DVAX Valuation

Dynavax Technologies Corp

Add to Watchlist

Advanced Chart

10.190

-0.07(-0.682%)1D

DVAX Relative Valuation

DVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DVAX is overvalued; if below, it's undervalued.

Historical Valuation

Dynavax Technologies Corp (DVAX) is now in the Fair zone, suggesting that its current forward PS ratio of 10.19 is considered Fairly compared with the five-year average of -4.47. The fair price of Dynavax Technologies Corp (DVAX) is between 7.43 to 10.23 according to relative valuation methord.

Relative Value

Fair Zone

7.43-10.23

Current Price：10.19

Fair

21.53

Trailing

Forward

73.56

EV/EBITDA

Dynavax Technologies Corp. (DVAX) has a current EV/EBITDA of 73.56. The 5-year average EV/EBITDA is 64.77. The thresholds are as follows: Strongly Undervalued below -332.61, Undervalued between -332.61 and -133.92, Fairly Valued between 263.45 and -133.92, Overvalued between 263.45 and 462.14, and Strongly Overvalued above 462.14. The current Forward EV/EBITDA of 73.56 falls within the Historic Trend Line -Fairly Valued range.

234.69

EV/EBIT

Dynavax Technologies Corp. (DVAX) has a current EV/EBIT of 234.69. The 5-year average EV/EBIT is 47.68. The thresholds are as follows: Strongly Undervalued below -134.53, Undervalued between -134.53 and -43.42, Fairly Valued between 138.79 and -43.42, Overvalued between 138.79 and 229.89, and Strongly Overvalued above 229.89. The current Forward EV/EBIT of 234.69 falls within the Strongly Overvalued range.

10.19

Dynavax Technologies Corp. (DVAX) has a current PS of 10.19. The 5-year average PS is 4.30. The thresholds are as follows: Strongly Undervalued below 0.80, Undervalued between 0.80 and 2.55, Fairly Valued between 6.05 and 2.55, Overvalued between 6.05 and 7.80, and Strongly Overvalued above 7.80. The current Forward PS of 10.19 falls within the Strongly Overvalued range.

0.00

P/OCF

Dynavax Technologies Corp. (DVAX) has a current P/OCF of 0.00. The 5-year average P/OCF is 32.60. The thresholds are as follows: Strongly Undervalued below -106.02, Undervalued between -106.02 and -36.71, Fairly Valued between 101.92 and -36.71, Overvalued between 101.92 and 171.23, and Strongly Overvalued above 171.23. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

18.95

P/FCF

Dynavax Technologies Corp. (DVAX) has a current P/FCF of 18.95. The 5-year average P/FCF is 50.49. The thresholds are as follows: Strongly Undervalued below -332.75, Undervalued between -332.75 and -141.13, Fairly Valued between 242.10 and -141.13, Overvalued between 242.10 and 433.72, and Strongly Overvalued above 433.72. The current Forward P/FCF of 18.95 falls within the Historic Trend Line -Fairly Valued range.

Dynavax Technologies Corp (DVAX) has a current Price-to-Book (P/B) ratio of 2.42. Compared to its 3-year average P/B ratio of 2.60 , the current P/B ratio is approximately -6.93% higher. Relative to its 5-year average P/B ratio of 6.30, the current P/B ratio is about -61.66% higher. Dynavax Technologies Corp (DVAX) has a Forward Free Cash Flow (FCF) yield of approximately 0.05%. Compared to its 3-year average FCF yield of 5.10%, the current FCF yield is approximately -98.94% lower. Relative to its 5-year average FCF yield of 5.22% , the current FCF yield is about -98.97% lower.

2.42

P/B

Median3y

2.60

Median5y

6.30

0.05

FCF Yield

Median3y

5.10

Median5y

5.22

Competitors Valuation Multiple

The average P/S ratio for DVAX's competitors is 23.46, providing a benchmark for relative valuation. Dynavax Technologies Corp Corp (DVAX) exhibits a P/S ratio of 10.19, which is -56.57% above the industry average. Given its robust revenue growth of 29.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DVAX.O

Dynavax Technologies Corp

Inhibrx Biosciences Inc

Syndax Pharmaceuticals Inc

Relay Therapeutics Inc

Performance Decomposition

Market capitalization of DVAX decreased by 20.76% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 73.80M to 95.44M.

The secondary factor is the Margin Expansion, contributed 27.15%to the performance.

Overall, the performance of DVAX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

29.33%

73.80M → 95.44M

Revenue Growth

27.15%

15.43 → 19.62

Margin Expansion

-77.24%

-106.45 → -24.23

P/E Change

-20.76%